D. J. Drucker, Enhancing Incretin Action for the Treatment of Type 2 Diabetes, Diabetes Care, vol.26, issue.10, pp.2929-2969, 2003.
DOI : 10.2337/diacare.26.10.2929

D. J. Drucker and M. A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, The Lancet, vol.368, issue.9548, pp.1696-705, 2006.
DOI : 10.1016/S0140-6736(06)69705-5

L. G. Hemkens, U. Grouven, R. Bender, C. Günster, S. Gutschmidt et al., Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study, Diabetologia, vol.180, issue.9, pp.1732-1776, 2009.
DOI : 10.1007/s00125-009-1418-4

H. M. Colhoun, Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group, Diabetologia, vol.40, issue.9, pp.1755-65, 2009.
DOI : 10.1007/s00125-009-1453-1

C. J. Currie, C. D. Poole, and E. A. Gale, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, vol.23, issue.9, pp.1766-77, 2009.
DOI : 10.1007/s00125-009-1440-6

J. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir et al., Insulin glargine use and short-term incidence of malignancies???a population-based follow-up study in Sweden, Diabetologia, vol.14, issue.9, pp.1745-54, 2009.
DOI : 10.1007/s00125-009-1444-2

C. Lu, Y. Sun, C. Muo, R. Chen, P. Chen et al., Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study, Cerebrovascular Diseases, vol.36, issue.2, pp.145-51, 2013.
DOI : 10.1159/000353679

S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini et al., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) http://care.diabetesjournals.org/content/early, 2012.

. Prévalence-et-incidence-du-diabète, . Et-mortalité-liée-au-diabète-en-france, and . Invs, http://www.invs.sante.fr/publications, 2010.

J. Holst, The Physiology of Glucagon-like Peptide 1, Physiological Reviews, vol.87, issue.4, 2007.
DOI : 10.1152/physrev.00034.2006

I. Incrétines and D. Et-inhibiteurs-de-la, 4 : homéostasie glucidique et diabète de type 2

R. Pratley and A. Salsali, Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes, Current Medical Research and Opinion, vol.23, issue.4, pp.919-950, 2007.
DOI : 10.1185/030079906X162746

E. Matteucci and O. Giampietro, Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme, Current Medicinal Chemistry, vol.16, issue.23, pp.2943-51, 2009.
DOI : 10.2174/092986709788803114

M. Victoza-liraglutide, Novo Nordisk Canada Inc. Mars, 2014.

J. Philippe, Role and indication of GLP-1 analogues in the treatment of type 2 diabetes, Rev Med Suisse, vol.5, pp.1260-1262, 2009.

C. W. Spellman, . Do, and . Phd, Pharmacology of GLP-1 Agonists: Describing the Therapeutic Potential to Patients, 2011.

D. Kim, L. Macconell, D. Zhuang, P. Kothare, M. Trautmann et al., Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes, Diabetes Care, vol.30, issue.6, pp.1487-93, 2007.
DOI : 10.2337/dc06-2375

D. Theodosios, . Filippatos, S. Moses, and . Elisaf, Effects of glucagon-like peptide-1 receptor agonists on renal function, 2013.

K. Hurren and N. Pinelli, Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Epub, 2012.

P. Kothare, H. Linnebjerg, Z. Skrivanek, S. Reddy, K. Mace et al., Exenatide effects on statin pharmacokinetics and lipid response, Int. Journal of Clinical Pharmacology and Therapeutics, vol.45, issue.02, 2007.
DOI : 10.5414/CPP45114

A. Randomised and . Double-blind, Cross-Over Trial Investigating the Effect of Liraglutide on the Absorption Pharmacokinetics of Concomitantly Administered Oral Drugs in Healthy Subjects. http://professional.diabetes.org/Content/Posters, 2008.

P. Kothare, M. Seger, N. J. Mace, K. Mitchell, M. Linnebjerg et al., Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial, BMC Clinical Pharmacology, vol.825, issue.1, 2012.
DOI : 10.1016/j.jchromb.2005.01.012

D. Soon, P. Kothare, H. Linnebjerg, S. Park, E. Yuen et al., Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men, The Journal of Clinical Pharmacology, vol.9, issue.2, 2006.
DOI : 10.1177/0091270006291622

M. Bush, R. Scott, P. Watanalumlerd, H. Zhi, and E. Lewis, Effects of Multiple Doses of Albiglutide on the Pharmacokinetics, Pharmacodynamics, and Safety of Digoxin, Warfarin, or a Low-Dose Oral Contraceptive, Postgraduate Medicine, vol.687, issue.12
DOI : 10.1177/0091270006291622

J. Bernard, Pancréatites médicamenteuses, 2014.

A. Scheen, GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris), pp.5-6515, 2013.

R. Defronzo, R. Ratner, J. Han, D. Kim, M. Fineman et al., Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes, Diabetes Care, vol.28, issue.5, 2005.
DOI : 10.2337/diacare.28.5.1092

J. Buse, R. Henry, J. Han, D. Kim, M. Fineman et al., Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes, Diabetes Care, vol.27, issue.11, p.113
DOI : 10.2337/diacare.27.11.2628

D. Kendall, M. Riddle, J. Rosenstock, D. Zhuang, D. Kim et al., Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea, Diabetes Care, vol.28, issue.5, 2005.
DOI : 10.2337/diacare.28.5.1083

R. Heine, V. Gaal, L. Johns, D. Mihm, M. Widel et al., Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes, Annals of Internal Medicine, vol.143, issue.8, 2005.
DOI : 10.7326/0003-4819-143-8-200510180-00006

M. Diamant, L. Van-gaal, S. Stranks, J. Northrup, D. Cao et al., Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland. subgroup data from a randomised multinational trial GWAA. GWAA Polish Study Group, p.24186595, 2010.

M. Marre, S. Shaw, and . Colagiuri, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26??weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type??2 diabetes (LEAD-1 SU), Diabetic Medicine, vol.284, issue.3, 2009.
DOI : 10.1111/j.1464-5491.2009.02666.x

M. Nauck, A. Frid, K. Hermansen, N. S. Shah, T. Tankova et al., Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study, Diabetes Care, vol.32, issue.1, 2009.
DOI : 10.2337/dc08-1355

A. Garber, R. Henry, R. Ratner, P. Garcia-hernandez, H. Rodriguez-pattzi et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial, The Lancet, vol.373, issue.9662, 2009.
DOI : 10.1016/S0140-6736(08)61246-5

B. Zinman, J. Gerich, J. Buse, A. Lewin, S. Schwartz et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). LEAD-4 Study Investigators, 2009.

J. Buse, J. Rosenstock, G. Sesti, W. Schmidt, E. Montanya et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), The Lancet, vol.374, issue.9683, 2009.
DOI : 10.1016/S0140-6736(09)60659-0

T. Vilsbøll, M. Christensen, E. Anders, . Junker, K. Filip et al., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, BMJ, vol.344, issue.jan10 2, p.7771, 2012.
DOI : 10.1136/bmj.d7771

M. Monami, I. Dicembrini, N. Marchionni, C. M. Rotella, and E. Mannucci, Effects of glucagonlike peptide-1 receptor agonists on body weight: a meta-analysis, 2012.

B. Sol, . Stylo, M. Byetta, S. Injectable, and S. Prerempli, Fiche(s) d'identité interopérable. Historique des références officielles

M. Nauck, Effects of exenatide compared with twice-daily triphasic insulin aspart in patients with type 2 diabetes using metformin and a sulphonylurea, 42nd annual meeting of the European Association of the Study of Diabetes, p.1, 2006.

T. Wadden, P. Hollander, S. Klein, K. Niswender, V. Woo et al., Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study, International Journal of Obesity, vol.289, issue.11, pp.1443-51, 2013.
DOI : 10.1161/01.CIR.0000111245.75752.C6

M. Katout, H. Zhu, J. Rutsky, P. Shah, R. Brook et al., Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic metaanalysis and meta-regression. janvier 2014

M. Cormack and P. L. , Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus, 2014.

A. B. Marino, S. W. Cole, and D. S. Nuzum, Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus, American Journal of Health-System Pharmacy, vol.71, issue.3, 2014.
DOI : 10.2146/ajhp130301

D. Yadav and A. Lowenfels, Trends in the Epidemiology of the First Attack of Acute Pancreatitis, Pancreas, vol.33, issue.4, pp.323-353, 2006.
DOI : 10.1097/01.mpa.0000236733.31617.52

M. Elashoff, A. Matveyenko, B. Gier, R. Elashoff, and P. Butler, Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1???Based Therapies, Gastroenterology, vol.141, issue.1, 2011.
DOI : 10.1053/j.gastro.2011.02.018

D. Dore, G. Bloomgren, M. Wenten, C. Hoffman, C. Clifford et al., A cohort study of acute pancreatitis in relation to exenatide use, Diabetes, Obesity and Metabolism, vol.53, issue.6, 2011.
DOI : 10.1111/j.1463-1326.2011.01376.x

S. Singh, H. Chang, T. Richards, J. Weiner, J. Clark et al., Glucagonlike Peptide 1???Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus, JAMA Internal Medicine, vol.173, issue.7, pp.534-543, 2013.
DOI : 10.1001/jamainternmed.2013.2720

J. Faillie, S. Babai, S. Crépin, V. Bres, M. Laroche et al., Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. The French Pharmacovigilance Centers Networkhttp://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Diabete-de-type-2- nouvelles-donnees-sur-le-risque-pancreatique-chez-les-patients-diabetiques-traites-par-lesincretinomimetiques-Point-d-information (Dernière consultation, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00922480

L. Li, J. Shen, M. Bala, J. Busse, S. Ebrahim et al., Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies, BMJ, vol.348, issue.apr15 2, 2014.
DOI : 10.1136/bmj.g2366

J. Romley, D. Goldman, M. Solomon, D. Mcfadden, and A. Peters, Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population, Diabetes Technology & Therapeutics, vol.14, issue.10, pp.904-915, 2012.
DOI : 10.1089/dia.2012.0075

D. Funch, H. Gydesen, K. Tornøe, A. Major-pedersen, and K. A. Chan, A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs, Diabetes, Obesity and Metabolism, vol.50, issue.3, pp.273-278, 2014.
DOI : 10.1111/dom.12230

H. Zhao, L. Wang, R. Wei, D. Xiu, M. Tao et al., Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Mars, 2014.

V. Aroda and R. Ratner, The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review, Diabetes/Metabolism Research and Reviews, vol.360, issue.Suppl. 1, 2011.
DOI : 10.1002/dmrr.1202

M. Jespersen, F. Knop, and M. Christensen, GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations, Expert Opinion on Drug Metabolism & Toxicology, vol.51, issue.1, 2012.
DOI : 10.2337/db10-1790

M. Fineman, K. Mace, M. Diamant, T. Darsow, B. Cirincione et al., Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes, Obesity and Metabolism, vol.30, issue.6, 2012.
DOI : 10.1111/j.1463-1326.2012.01561.x

J. Buse, A. Garber, J. Rosenstock, W. Schmidt, J. Brett et al., Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.6, pp.1695-702, 2011.
DOI : 10.1210/jc.2010-2822

B. Knudsen, L. Madsen, L. Andersen, S. Almholt, K. De-boer et al., Glucagon-like Peptide-1 receptor agonists activate rodent thyroid Ccells causing calcitonin release and C-cell proliferation, 2010.

B. Gier, P. Butler, C. Lai, D. Kirakossian, M. Denicola et al., Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.1, 2012.
DOI : 10.1210/jc.2011-2407

A. Michael, N. Nauck, and P. Friedrich, Do GLP-1?Based Therapies Increase Cancer Risk? http://care.diabetesjournals.org/content, pp.245-280

B. Waser, K. Beetschen, N. Pellegata, and J. Reubi, Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy, Neuroendocrinology, vol.94, issue.4, 2011.
DOI : 10.1159/000330447

Y. Sun, L. Fan, J. Meng, F. Zhang, D. Zhang et al., Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer? 2013 Dec

A. Kakkar, GLP-1 receptor agonists and the risk of colorectal cancer, Medical Hypotheses, vol.82, issue.6
DOI : 10.1016/j.mehy.2014.03.028

T. Rieg, M. Gerasimova, F. Murray, T. Masuda, T. Tang et al., Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice, AJP: Renal Physiology, vol.303, issue.7, 2012.
DOI : 10.1152/ajprenal.00259.2012

D. Theodosios, . Filippatos, S. Moses, and . Elisaf, Effects of glucagon-like peptide-1 receptor agonists on renal function, 2013.

M. Pawaskar, K. Tuttle, Q. Li, J. Best, and P. Anderson, Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine, Annals of Pharmacotherapy, vol.76, issue.5, 2014.
DOI : 10.1162/003465302317331982

R. Krishna, A. Bergman, P. Larson, J. Cote, K. Lasseter et al., Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects, The Journal of Clinical Pharmacology, vol.57, issue.2, 2007.
DOI : 10.1177/0091270006296523

X. Chu, K. Bleasby, J. Yabut, X. Cai, G. Chan et al., Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein, Journal of Pharmacology and Experimental Therapeutics, vol.321, issue.2, 2007.
DOI : 10.1124/jpet.106.116517

A. Scheen, Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions, Clinical Pharmacokinetics, vol.50, issue.1, 2010.
DOI : 10.1007/BF03257472

C. Patel, L. Li, S. Girgis, D. Kornhauser, E. Frevert et al., Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole, Clinical Pharmacology: Advances and Applications, 2011.
DOI : 10.2147/CPAA.S15227

V. Upreti, D. Boulton, L. Li, A. Ching, H. Su et al., Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects, British Journal of Clinical Pharmacology, vol.17, issue.1, 2011.
DOI : 10.1111/j.1365-2125.2011.03937.x

E. Larger, Mécanisme d'action des inhibiteurs de la dipeptidyl-peptidase IV

N. Brown, S. Byiers, D. Carr, M. Maldonado, and B. Warner, Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema, Hypertension, vol.54, issue.3, 2009.
DOI : 10.1161/HYPERTENSIONAHA.109.134197

B. Richter, E. Bandeira-echtler, K. Bergerhoff, and C. Lerch, Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus (Review) The Cochrane Collaboration, 2009.

M. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. Stein, Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, 2007.

K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami et al., Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, 2007.

J. Rosenstock, M. Baron, S. Dejager, D. Mills, and A. Schweizer, Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial, Diabetes Care, vol.30, issue.2, 2007.
DOI : 10.2337/dc06-1815

G. Bolli, F. Dotta, E. Rochotte, and S. Cohen, Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study, Diabetes, Obesity and Metabolism, vol.49, issue.0, 2008.
DOI : 10.1111/j.1464-5491.2004.01426.x

B. Göke, K. Hershon, D. Kerr, C. Pascual, A. Schweizer et al., Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin, 2008.

J. Rosenstock, C. Aguilar-salinas, E. Klein, S. Nepal, J. List et al., CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes, 2009.

R. Amori, J. Lau, and A. Pittas, Efficacy and Safety of Incretin Therapy in Type 2 Diabetes, JAMA, vol.298, issue.2, 2007.
DOI : 10.1001/jama.298.2.194

D. Wu, L. Li, and C. Liu, Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. janvier 2014

T. Karagiannis, P. Paschos, K. Paletas, D. Matthews, and A. Tsapas, Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis, BMJ, vol.344, issue.mar12 1, 2012.
DOI : 10.1136/bmj.e1369

X. Liu, X. Q. Zhang, L. Yang, Q. Liu, X. Xu et al., The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type-2 diabetes mellitus-a meta-analysis. Mars, 2014.

J. Green, M. Bethel, S. Paul, A. Ring, K. Kaufman et al., Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. dec 2013

N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction, Endocrine, vol.44, issue.1
DOI : 10.1007/s12020-014-0175-4

W. White, G. Bakris, R. Bergenstal, C. Cannon, W. Cushman et al., EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE), American Heart Journal, vol.162, issue.4, pp.620-626, 2011.
DOI : 10.1016/j.ahj.2011.08.004

A. Scheen, Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes, Postgraduate Medicine, vol.110, issue.6, 2013.
DOI : 10.1016/S0140-6736(12)60691-6

D. Reinhold, A. Biton, and A. Goihl, Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses, Annals of the New York Academy of Sciences, vol.517, issue.1, pp.402-409, 2007.
DOI : 10.1084/jem.20042276

M. Willemen, A. Mantel-teeuwisse, S. Straus, R. Meyboom, T. Egberts et al., Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase. 2011; Diabetes Care, Feb, vol.34, issue.2, pp.369-74, 2011.

M. A. Thompson, K. Ohnuma, M. Abe, C. Morimoto, and N. H. Dang, CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders, Mini-Reviews in Medicinal Chemistry, vol.7, issue.3, pp.253-73, 2007.
DOI : 10.2174/138955707780059853

V. C. Luft, M. I. Schmidt, J. S. Pankow, R. C. Hoogeveen, D. Couper et al., Dipeptidyl Peptidase IV and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) study, Diabetes Care, vol.33, issue.5, pp.1109-1120, 2010.
DOI : 10.2337/dc09-1996

K. Alexandraki, C. Piperi, C. Kalofoutis, J. Singh, A. Alaveras et al., Inflammatory Process in Type 2 Diabetes: The Role of Cytokines, Annals of the New York Academy of Sciences, vol.45, issue.1, pp.89-117, 2006.
DOI : 10.1074/jbc.M404962200

N. Joshi, G. Caputo, M. Weitekamp, and A. Karchmer, Infections in Patients with Diabetes Mellitus, New England Journal of Medicine, vol.341, issue.25
DOI : 10.1056/NEJM199912163412507

L. M. Muller, K. J. Gorter, E. Hak, W. L. Goudzwaard, F. G. Schellevis et al., Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study, pp.2012-38550, 2005.

R. Noel, D. Braun, R. Patterson, and G. Bloomgren, Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study, Diabetes Care, vol.32, issue.5, pp.834-842, 2009.
DOI : 10.2337/dc08-1755

M. Elashoff, A. Matveyenko, B. Gier, R. Elashoff, and P. Butler, Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1???Based Therapies, Gastroenterology, vol.141, issue.1, 2011.
DOI : 10.1053/j.gastro.2011.02.018

M. Monami, I. Dicembrini, and E. Mannucci, Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials, Diabetes, Obesity and Metabolism, vol.11, issue.1, 2013.
DOI : 10.1111/dom.12176

M. K. Garg, S. Kharb, and A. Pandit, Prescribing gliptins: Enthusiasm should be coupled with caution, Indian Journal of Endocrinology and Metabolism, vol.16, issue.2, 2012.
DOI : 10.4103/2230-8210.93785

K. Aston-mourney, S. Subramanian, S. Zraika, T. Samarasekera, D. Meier et al., One year of sitagliptin treatment protects against islet amyloid-associated ??-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice, AJP: Endocrinology and Metabolism, vol.305, issue.4, 2013.
DOI : 10.1152/ajpendo.00025.2013

T. Olli, . Raitakari, S. David, and . Celermajer, Flow-mediated dilatation, 2000.

M. Ayaori, . Md, N. Phd, M. Iwakami, K. Ikewaki et al., Dipeptidyl Peptidase-4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow-Mediated Vasodilatation in Type 2 Diabetic Patients, Journal of the American Heart Association, vol.2, issue.1
DOI : 10.1161/JAHA.112.003277

K. Skandalis, G. Gaitanis, A. Tsartsarakis, and I. Bassukas, Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin, Journal of the European Academy of Dermatology and Venereology, vol.161, issue.2, pp.249-53, 2012.
DOI : 10.1111/j.1468-3083.2011.04062.x

R. Pratley, . Nauck, . Bailey, . Montanya, . Cuddihy et al., One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, International Journal of Clinical Practice, vol.154, issue.Suppl. 3, 2011.
DOI : 10.1111/j.1742-1241.2011.02656.x

B. Gallwitz, Anorexigenic Effects of GLP-1 and Its Analogues, Handb Exp Pharmacol, vol.209, pp.185-207, 2012.
DOI : 10.1007/978-3-642-24716-3_8

J. Ussher and D. Drucker, Cardiovascular Biology of the Incretin System, Endocrine Reviews, vol.33, issue.2, pp.187-215, 2012.
DOI : 10.1210/er.2011-1052

S. Nikfar, M. Abdollahi, and P. Salari, The Efficacy and Tolerability of Exenatide in Comparison to Placebo; A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Journal of Pharmacy & Pharmaceutical Sciences, vol.15, issue.1, pp.1-30, 2012.
DOI : 10.18433/J3G883

M. Monami, C. Lamanna, C. Desideri, and E. Mannucci, DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis, Advances in Therapy, vol.27, issue.1, pp.14-25, 2012.
DOI : 10.1007/s12325-011-0088-z

A. Scheen, Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes, European Journal of Internal Medicine, vol.23, issue.2, pp.126-157, 2012.
DOI : 10.1016/j.ejim.2011.10.007

F. Ismail-beigi, E. Moghissi, and M. Tiktin, Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials, Annals of Internal Medicine, vol.154, issue.8, pp.554-563, 2011.
DOI : 10.7326/0003-4819-154-8-201104190-00007

S. Akalin, K. Berntorp, and A. Ceriello, Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control, International Journal of Clinical Practice, vol.358, issue.10, pp.1421-1426, 2009.
DOI : 10.1111/j.1742-1241.2009.02165.x

S. J. Lee and C. Eng, Goals of Glycemic Control in Frail Older Patients With Diabetes, JAMA, vol.305, issue.13, pp.1350-1351, 2011.
DOI : 10.1001/jama.2011.404

H. Gerstein, M. Miller, and R. Byington, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, vol.358, pp.2545-59, 2008.

F. Turnbull, C. Abraira, and R. Anderson, Intensive glucose control and macrovascular outcomes in type 2 diabetes, Diabetologia, vol.359, issue.11, pp.2288-982470, 2009.
DOI : 10.1007/s00125-009-1470-0

S. Halimi, Recommandations HAS-ANSM 2013 versus prise de position ADA-EASD 2012 : convergences et divergences ? SFD, 2013.

A. Blanchet and A. Gotman, L'entretien: L'enquête et ses méthodes. 2 ème édition Armand colin, pp.2011-142